however, when recombinant IGF-1 is co-administrated with recombinant GH, circulating leptin levels are unexpectedly elevated, likely due to GH stimulatory effects on insulin production.87 Moreover, treatment with recombinant GH increases IGF-1 levels in patients undergoing hemodialysis with low protein intake, resulting in a positive nitrogen balance and suggesting an anabolic response, which may also contribute to increase the leptin levels.88 Of note, among the multiple factors, circulating IGF-1 concentration is strongly associated with loss of appetite in dialysis patients, a condition linked to poor clinical outcomes.89 However, very low IGF-1 levels have been associated with a higher mortality in CKD patients with poor muscle strength, whereas those with higher muscle strength showed improved survival despite of the reduced IGF-1 concentration.90 This suggests that muscle effects, potentially influenced by physical exercise habits or muscle-derived cytokines (myokines), may play a role in these outcomes

With a background in orthopaedics, he brings a deep understanding of musculoskeletal health and recovery to every treatment plan
Treatment recommendations are made only after provider evaluation and clinical assessment
CJC-1295 No DAC + Ipamorelin Multi-Compound Research Formulation